Cargando…

PD-L1 – inhibitors in neuroendocrine neoplasia: Results from a real-life study

Immune check-point inhibitors (ICIs) have changed our view on how to treat cancer. Despite their approval in treatment of many different cancers, efficacy of immune check-point inhibitors (ICI) in neuroendocrine neoplasia is limited and poorly understood. Established treatment options of neuroendocr...

Descripción completa

Detalles Bibliográficos
Autores principales:	Özdirik, Burcin, Jann, Henning, Bischoff, Philip, Fehrenbach, Uli, Tacke, Frank, Roderburg, Christoph, Wiedenmann, Bertram
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2021
Materias:	5700
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7793325/ https://www.ncbi.nlm.nih.gov/pubmed/33429744 http://dx.doi.org/10.1097/MD.0000000000023835

Ejemplares similares

A case report of an excellent response to interferon- α in a patient with functional metastasized neuroendocrine tumor refractory to other treatments
por: Özdirik, Burcin, et al.
Publicado: (2020)

A rare case of a patient with a high grade neuroendocrine tumor developing neutropenic sepsis after receiving PRRT combined with Capecitabine or Temozolomide: A case report
por: Özdirik, Burcin, et al.
Publicado: (2021)

Primary Neuroendocrine Neoplasms of the Breast: Case Series and Literature Review
por: Özdirik, Burcin, et al.
Publicado: (2020)

Atezolizumab and bevacizumab-induced encephalitis in advanced hepatocellular carcinoma: Case report and literature review
por: Özdirik, Burcin, et al.
Publicado: (2021)

Soluble Urokinase Plasminogen Activator Receptor (suPAR) Concentrations Are Elevated in Patients with Neuroendocrine Malignancies
por: Özdirik, Burcin, et al.
Publicado: (2020)

The Role of miRNA in the Pathophysiology of Neuroendocrine Tumors
por: Geisler, Lukas, et al.
Publicado: (2021)

Analysis of miR-29 Serum Levels in Patients with Neuroendocrine Tumors—Results from an Exploratory Study
por: Özdirik, Burcin, et al.
Publicado: (2020)

Somatostatin Analogues in the Treatment of Neuroendocrine Tumors: Past, Present and Future
por: Stueven, Anna Kathrin, et al.
Publicado: (2019)

Serum levels of miR-223 but not miR-21 are decreased in patients with neuroendocrine tumors
por: Hellberg, Teresa, et al.
Publicado: (2020)

Osteopontin is a prognostic circulating biomarker in patients with neuroendocrine neoplasms
por: Kidess, Evelyn, et al.
Publicado: (2023)

Systemic treatment of hepatocellular carcinoma: from sorafenib to combination therapies
por: Roderburg, Christoph, et al.
Publicado: (2020)

In Vivo Models for Cholangiocarcinoma—What Can We Learn for Human Disease?
por: Mohr, Raphael, et al.
Publicado: (2020)

Neuroendocrine tumors in a patient with multiple endocrine neoplasia type 1 syndrome: A case report and review of the literature
por: Deng, Jian, et al.
Publicado: (2023)

Lessons From Immune Checkpoint Inhibitor Trials in Hepatocellular Carcinoma
por: Mohr, Raphael, et al.
Publicado: (2021)

Elevated Flt3L Predicts Long-Term Survival in Patients with High-Grade Gastroenteropancreatic Neuroendocrine Neoplasms
por: Detjen, Katharina M., et al.
Publicado: (2021)

Pathological pseudoprogression to anti-PD-1 inhibitor in metastatic periampullary carcinoma: Case report
por: Wang, Junhui, et al.
Publicado: (2023)

Neuron - specific enolase predicts the prognosis in advanced small cell lung cancer patients treated with first-line PD-1/PD-L1 inhibitors
por: Li, Lingling, et al.
Publicado: (2021)

Gastric neuroendocrine neoplasias: manifestations and comparative outcomes
por: Felder, S, et al.
Publicado: (2019)

Primary leptomeningeal melanomatosis successfully treated with PD-1 inhibitor pembrolizumab: A case report
por: Misir Krpan, Ana, et al.
Publicado: (2020)

Distribution of gastrointestinal neuroendocrine tumors in Europe: results from a retrospective cross-sectional study
por: Loosen, Sven H., et al.
Publicado: (2022)

The efficacy and safety of PD-1/PD-L1 inhibitors versus chemotherapy in patients with previously treated advanced non-small-cell lung cancer: A meta-analysis
por: Wu, Lin-guang-jin, et al.
Publicado: (2021)

Update in clinical management for gallbladder neuroendocrine carcinoma
por: Chu, Hongwu, et al.
Publicado: (2021)

A real-world study of recombinant human endostatin combined with PD-1/PD-L1 blockade and chemotherapy for patients with advanced non-small cell lung cancer negative for actionable molecular biomarkers
por: Zhao, Jing-Wen, et al.
Publicado: (2023)

Risk of gastrointestinal toxicities with PD-1 inhibitors in cancer patients: A meta-analysis of randomized clinical trials
por: Wei, Wei, et al.
Publicado: (2017)

Automatized Hepatic Tumor Volume Analysis of Neuroendocrine Liver Metastases by Gd-EOB MRI—A Deep-Learning Model to Support Multidisciplinary Cancer Conference Decision-Making
por: Fehrenbach, Uli, et al.
Publicado: (2021)

The Role of Microbiota in Primary Sclerosing Cholangitis and Related Biliary Malignancies
por: Özdirik, Burcin, et al.
Publicado: (2021)

Whole genome sequencing in high-grade cervical intraepithelial neoplasia patients from different ethnic groups in China
por: Wang, Jingjing, et al.
Publicado: (2023)

Treatment Approaches and Outcome of Patients with Neuroendocrine Neoplasia Grade 3 in German Real-World Clinical Practice
por: Luecke, Simone, et al.
Publicado: (2022)

Prognostic Significance of Programmed Cell Death 1 (PD-1) or PD-1 Ligand 1 (PD-L1) Expression in Epithelial-Originated Cancer: A Meta-Analysis
por: Zhang, Yaxiong, et al.
Publicado: (2015)

Diagnostic accuracy of (18)F-FDG PET/CT for detecting synchronous advanced colorectal neoplasia in patients with gastric cancer
por: Choi, Byung Wook, et al.
Publicado: (2016)

Well-differentiated neuroendocrine tumor of the stomach: A rare case at an uncommon site
por: Gumuscu, Burak, et al.
Publicado: (2016)

Sarcoidosis mimicking metastatic progression of pancreatic neuroendocrine tumor: A case report
por: Lolli, Ivan, et al.
Publicado: (2017)

Neuroendocrine carcinoma of the nasal cavity with epiphora as the first symptom: A case report
por: Wu, Weiqi, et al.
Publicado: (2020)

Efficacy and safety of PD1/PDL1 inhibitors combined with radiotherapy and anti-angiogenic therapy for solid tumors: A systematic review and meta-analysis
por: Xian, Feng, et al.
Publicado: (2023)

Inflammatory Cytokines Associated with Diagnosis, Tumor Grade and Prognosis in Patients with Neuroendocrine Tumors
por: Geisler, Lukas, et al.
Publicado: (2022)

Endocan expression is correlated with poor progression-free survival in patients with pancreatic neuroendocrine tumors
por: Lin, Liang-Yu, et al.
Publicado: (2017)

Synchronous multiple carcinoma with small intestine and pulmonary neuroendocrine involvement: A case report
por: Shan, Binbin, et al.
Publicado: (2017)

Clinicopathological characteristics and survival outcomes in neuroendocrine prostate cancer: A population-based study
por: Zhu, Jiamin, et al.
Publicado: (2021)

Prognostic value of lactate dehydrogenase for melanoma patients receiving anti-PD-1/PD-L1 therapy: A meta-analysis
por: Xu, Jun, et al.
Publicado: (2021)

From Liver Cirrhosis to Cancer: The Role of Micro-RNAs in Hepatocarcinogenesis
por: Mohr, Raphael, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_qve1tk7d8atklsp198n4jmg1m8